Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Real World Data
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Algeta
Evaluate
December 19, 2016
Interview – Nordic Nanovector exits a glowing year
December 09, 2016
Snippet roundup: Ash cash rolls in, Voyager boldly goes, but Northwest heads south
January 20, 2016
Asco-GI preview – Lutathera delivers again
March 04, 2015
Bristol bets that yesterday’s prostate vaccine could score tomorrow
February 28, 2014
Bankers pitching biotech acquisitions to Bayer must fight hard
January 29, 2014
As Xtandi Prevails, Medivation stays ahead of the curve
November 26, 2013
At long last Bayer makes offer for Algeta
October 10, 2013
Bayer shows big pharma that a conglomerate can do it too
September 13, 2013
Yervoy’s prostate cancer flop points the way to another combo
August 12, 2013
Dendreon’s hero to goat story reaches crisis stage
June 06, 2013
Asco Event Analyzer – 2013’s winners and losers
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics